1. Home
  2. BHF vs CRNX Comparison

BHF vs CRNX Comparison

Compare BHF & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brighthouse Financial Inc.

BHF

Brighthouse Financial Inc.

HOLD

Current Price

$62.10

Market Cap

3.7B

Sector

Finance

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$39.05

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHF
CRNX
Founded
2016
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.9B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BHF
CRNX
Price
$62.10
$39.05
Analyst Decision
Hold
Strong Buy
Analyst Count
8
8
Target Price
$57.71
$76.63
AVG Volume (30 Days)
479.7K
1.0M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
$27.10
$720.10
Revenue Next Year
$1.09
$184.67
P/E Ratio
$4.34
N/A
Revenue Growth
N/A
N/A
52 Week Low
$43.16
$25.83
52 Week High
$66.33
$57.99

Technical Indicators

Market Signals
Indicator
BHF
CRNX
Relative Strength Index (RSI) 60.26 50.06
Support Level $59.04 $33.19
Resistance Level $64.37 $45.32
Average True Range (ATR) 0.66 1.42
MACD 0.23 0.41
Stochastic Oscillator 78.15 55.99

Price Performance

Historical Comparison
BHF
CRNX

About BHF Brighthouse Financial Inc.

Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: